Results 21 to 30 of about 19,378,005 (296)

Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning

open access: yes, 2022
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

open access: yes, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor   +8 more
core   +1 more source

Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia

open access: yes, 2020
Dataset of the study “Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia”
Jiakui Zhang (8521494)   +16 more
core   +2 more sources

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. [PDF]

open access: yesAdv Sci (Weinh)
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Wang L   +8 more
europepmc   +2 more sources

Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific [PDF]

open access: yes, 1998
Acute HIV infection is associated with a vigorous immune response characterized by the proliferation of selected T cell receptor V beta (BV)-expressing CD8(+) T cells.
Ogg, GS   +19 more
core   +1 more source

Chimeric Antigen Receptor T-cell Therapy (CAR T)

open access: yes, 2022
This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T ...
Dr. Vachaspati Narayan, Dr. Mahender Miland, Dr. Kritika Gahlot, Dr. Mukul Purva
core   +1 more source

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope [PDF]

open access: yesFrontiers in Pharmacology, 2021
Cancer is among the leading causes of death worldwide. Therefore, improving cancer therapeutic strategies using novel alternatives is a top priority on the contemporary scientific agenda. An example of such strategies is immunotherapy, which is based on teaching the immune system to recognize, attack, and kill malignant cancer cells.
Alejandrina Hernández-López   +4 more
openaire   +3 more sources

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

open access: yesJACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS   +12 more
doaj   +1 more source

Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy

open access: yesIDCases, 2021
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel treatment for various types of hematologic malignancy. We presented a case of refractory diffuse large B cell lymphoma patient who developed acute invasive fungal rhinosinusitis (AIFR) from ...
Supavit Chesdachai   +4 more
doaj   +1 more source

Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities

open access: yes, 2020
Chimeric antigen receptor T cell therapies for thoracic cancers— challenges and ...
Slaney, CY   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy